GleamWall
中文EN

PMVP PMV Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1699382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.0%
TTM EPS YoY1.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.4%
ROA-72.2%
ROIC (approx.)-100.2%
Asset turnover—

Leverage & solvency

Liabilities / assets48.7%
Debt / equity0.00x
Current ratio9.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$16.06M$14.68M$15.33M$15.83M$18.21M$18.40M$17.44M$13.77M
SG&A expense$4.00M$4.21M$3.69M$3.42M$4.31M$4.48M$4.12M$11.40M
Operating income-$20.06M-$18.88M-$19.02M-$19.24M-$22.52M-$22.88M-$21.56M-$25.17M
Pretax income-$34.38M-$18.08M-$18.04M-$18.01M-$21.07M-$21.20M-$19.63M-$23.00M
Income tax-$7,000$3,000—$26,000-$6,000$5,000-$2.20M$0
Net income-$34.37M-$18.09M-$18.04M-$18.04M-$21.06M-$21.21M-$17.44M-$23.00M
EBITDA-$20.04M-$18.86M-$18.98M-$19.21M-$22.49M-$22.85M-$21.53M-$25.13M
EPS (basic)-0.52-0.34-0.34—-0.40-0.41-0.34—
EPS (diluted)-0.52-0.34-0.34—-0.40-0.41-0.34—
Weighted avg. shares (diluted)66.23M53.39M53.33M—52.99M52.01M51.95M—
Banking
Net interest income$830,000$788,000$980,000$1.23M$1.48M$1.69M$1.94M$2.29M
Balance sheet
Cash & equivalents$19.99M$12.47M$39.13M$37.98M$36.34M$44.13M$51.34M$40.88M
Short-term investments$82.57M$66.96M$54.42M$74.96M$92.91M$98.15M$109.05M$128.58M
Current assets$104.89M$81.41M$95.78M$115.23M$132.45M$145.31M$163.50M$175.66M
PP&E, net$131,000$154,000$203,000$237,000$255,000$287,000$376,000$409,000
Total assets$111.40M$82.07M$96.56M$116.56M$133.84M$152.85M$170.61M$191.29M
Current liabilities$10.69M$10.57M$8.60M$11.41M$12.30M$11.61M$9.76M$14.37M
Total liabilities$54.30M$10.57M$8.60M$11.85M$12.85M$12.25M$10.50M$15.21M
Shareholders' equity$57.11M$71.50M$87.97M$104.71M$121.00M$140.60M$160.11M$176.08M
Shares outstanding75.53M53.46M53.33M53.33M52.99M52.99M51.95M51.94M
Cash flow statement
Operating cash flow-$18.18M-$14.58M-$19.68M-$17.19M-$19.82M-$18.30M-$18.27M-$16.66M
Capital expenditure$0$0$0$15,000-$1,000$11,000$4,000$56,000
Free cash flow-$18.18M-$14.58M-$19.68M-$17.20M-$19.82M-$18.31M-$18.27M-$16.72M
Investing cash flow-$21.20M-$12.23M$20.82M$18.44M$12.03M$10.99M$28.71M$7.74M
Financing cash flow$46.91M$143,000$0$392,000$0$103,000$10,000$172,000
Depreciation & amortization$23,000$24,000$34,000$33,000$32,000$32,000$37,000$39,000
Stock-based compensation$1.60M$1.54M$1.39M$1.36M$1.38M$1.67M$1.51M$1.27M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.